Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • TA321
  • Published: 

 Health Technology Appraisal

 Review of NICE Technology Appraisal Guidance No.321; Dabrafenib for treating advanced unresectable or metastatic BRAFV600 mutation-positive melanoma.

 Proposal to move the existing guidance to the static list

  As you may be aware the planned date for review of the above guidance was October 2017.

 This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

 No new evidence or trials have emerged that are expected to substantially change the recommendations in TA321. 

 Consequently we propose that TA321 should move to the ‘static list’ of technology appraisals.

 Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

This page was last updated: